Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacia & Upjohn submit pramipexole NDA for Parkinson's disease monotherapy.

Executive Summary

PHARMACIA & UPJOHN PRAMIPEXOLE PARKINSON's THERAPY NDA SUBMITTED Dec. 28. Pramipexole, which was discovered by Boehringer Ingelheim and co-developed by Upjohn, is a dopamine agonist. The company claims that the compound shows preferential D3 agonist activity compared to a mixed agonist/antagonist profile of other dopamine agents, that it is a full dopamine agonist and that it binds more selectively to dopamine receptors.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts